Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: The various aspects presented herein relate to methods for the reduction, prevention and/or inhibition of the oxidation of perfume ingredients, formulated perfumes, formulated body care products, formulated skin care products, formulated homecare products, essential oils, food raw materials, formulated food products and natural extracts.

Abstract: Disclosed herein are methods, assays, compositions and kits for the detection and measurement of UDP-glucose in biological samples. The methods, assays, compositions and kits are suitable for use with equipment that is readily available in a clinical laboratory, and permit rapid and reproducible detection and measurement of UDP-glucose at physiologically relevant levels in biological samples.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: Disclosed herein are methods, assays, compositions and kits for the detection and measurement of UDPglucose in biological samples. The methods, assays, compositions and kits are suitable for use with equipment that is readily available in a clinical laboratory, and permit rapid and reproducible detection and measurement of UDP-glucose at physiologically relevant levels in biological samples.

Abstract: The invention provides methods of monitoring for renal inflammation in a kidney transplantation donor or recipient by analyzing levels one or more UDP-hexoses (such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-glucosamine and/or N-acetyl-UDP-galactosamine) in sample from the donor or recipient. The invention also provides methods of treating or preventing renal inflammation in a kidney transplantation donor or recipient by providing a P2Y 14 receptor antagonist to the donor, the extracted kidney, or the recipient.

Abstract: The invention provides methods of monitoring development of renal inflammation in a subject following administration of a nephrotoxic agent. The methods involve analyzing levels of one or more UDP-hexoses, such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-glucosamine, or N-acetyl-UDP-galactosamine, in a sample from the subject. The invention also provides methods of treating or preventing renal inflammation in a subject who has been given a nephrotoxic agent by providing a P2Y 14 receptor antagonist to the subject.

Abstract: The invention provides methods of monitoring development of renal inflammation in a subject who has an infection by analyzing levels of one or more UDP-hexoses, such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-glucosamine or N-acetyl-UDP-galactosamine, in a sample from the subject. The invention also provides methods of treating or preventing renal inflammation in a subject who has an infection by providing a P2Y14 receptor antagonist to the subject.

Abstract: The invention provides methods of monitoring development of renal inflammation in a subject who has undergone a cardiac procedure and has had a cardiac event by analyzing levels of one or more UDP-hexoses (such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-glucosamine and/or N-acetyl-UDP-galactosamine) in a sample from the subject. The invention also provides methods of treating or preventing renal inflammation in a subject who has had a cardiac procedure, will have a cardiac procedure, or has had a cardiac event by providing a P2Y 14 receptor antagonist to the subject. The invention further provides methods for evaluating cardiac health in a subject. Finally, the invention provides methods of monitoring one or more UDP-hexoses (such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-glucosamine and/or N-acetyl-UDP-galactosamine) in a subject.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: Disclosed herein are methods, assays, compositions and kits for the detection and measurement of UDPglucose in biological samples. The methods, assays, compositions and kits are suitable for use with equipment that is readily available in a clinical laboratory, and permit rapid and reproducible detection and measurement of UDP-glucose at physiologically relevant levels in biological samples.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: The present disclosure relates to assays and methods for the detection of renal inflammation by measuring the level of P2Y14 and/or UDP-glucose in a sample from a subject, such as a urine sample. The present disclosure also relates to methods for the treatment of renal inflammation by administering a P2Y14 inhibitor.

Abstract: The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory-related complications in a subject by inhibiting the release of nitric oxide from basal cells in the respiratory tract.